

Dr. rer. nat. Dr. med. Kurt-Wilhelm Stahl

60, Günterstalstr. D-79100 Freiburg
Phone office +49-761-701370 fax +49-761-701374 mobile +49—(0)160-91911291

stahlkw@waisenmedizin.org

OBJECTIVE: 9th Conference of Applied Hygiene, Microbiology and Virology Dr. BRILL Institutes Hamburg Lecture "LeiProtect® our neglected hygienic reverse for the neglected infectious wound disease Cutaneous Leishmaniasis – Why?"

PROFESSIONAL EMPLOYMENT

Since 2000 ongoing	Head of the non-profit NGO Waisenmedizin (WM e.V.) https://waisenmedizin.org which promotes access to care with essential medicine as a human right acc. to the revised EU Social Charta, Articles 11 and 13; WM e. V. and cooperates with the Universities of Erlangen and Freiburg
Since retirement in 2003	Senior Expert listed by the Senior Expert Service (SES) with missions to Afghanistan, Pakistan, Iran, Lebanon and Algeria
2004 - 2012	Operating " stahl health care " scientific consultancy for pharmaceutical products (since 1989) focussing on: Scientific product evaluation, innovation transfer, strategic product developmental as well as regulatory advice and expertise.
1989 - 2003	Expert to the C.I / dg13 of the EU Commission, within the 5 th (cell factory & infectious diseases / orphan drugs) & 4 th frameworks (technology validation)
1999 - 2002	Professor of Biochemistry in an extracurricular capacity (apl.) Medical School of Hannover.
Since 1989	
1984- 1989	R & D Director, Technology Park Heidelberg. Developed a novel co-mitogenic oxidant principle for promotion of wound healing and for facilitating tissue repair in other parts of the body, (e. g. bone marrow, skin,) as an anti-iatrogenic adjunct treatment after cytostatic therapy. Also administered a federal (BMFT) grant and promoted knowledge transfer from university to industry.
1986- 1988	Professeur Conventionné, Pharmaceutical Faculty ULP Strasbourg Lectured before students of pharmacy on immunopharmacology directed research programmes for drug development.
1983- 1986	Senior Drug Evaluation Scientist. Evaluated new products for in licensing purposes for various pharmaceutical SMEs.
1982- 1983	Medical Director Head of the Medical Department of Midi-Labaz Arzneimittel, a German pharmaceutical branch of the French multinational SANOFI. Coordinated drug risk management before the Health Authorities and clinical phase 4 trials.
1981- 1982	Senior Scientist, Institute of Pathology, University of Freiburg. In charge of a research program analyzing DNA from rodents previously treated with alkylating carcinogens (Federal BMFT grant).
1978- 1980	Professeur Associé U. Paris XI & Institute of Oncology Villejuif (Director Georges Mathé) Research work on macrophages and cancer granted by the Mildred Scheel Foundation and the Ligue Nationale Contre le Cancer.
1976- 1977	Embo Senior fellow, Immunopathology, Molecular Biology (Director François Jacob) Pasteur Institute Paris. Analyzing an anti-inflammatory peptide underlying the macrophago-toxic effect of malignant cells
1975to 1976	Post Doc Radiology Department, Medical School of HANOVER internal medicine trainee period
1967to 1975	Post Doc & Research Assistant Biochemistry Department, Medical School of HANOVER introduced high pressure liquid chromatography

	(hplc) into analytical biochemistry
1963 to 1966	Medizinalassistent, University of Freiburg Exp. Oncology / Clin. Chemistry Urban Krankenhaus, Berlin-Kreuzberg Internal Medicine / Surgery Kreiskrankenhaus Peine , Gynaecology

Research interests

Reactive oxygen species (ROS) in chronic wounds, involvement of immune system in host defence and tissue regeneration, interests actually focussed on the interface between basic research and applied clinical research under cost / benefit aspects in underdeveloped countries.

Since 2004 involved in clinical studies with leishmania patients in Afghanistan elaborating trial monitoring by electronic medicine and elaboration of a standard web -based protocol for leishmania patients.

Language Knowledge (WHO code)

Mother tongue in <i>italics</i>	Speak	Read	Write ^[1-3]
English (Intermediate London Chamber of Commerce Certificate)	3	3	3 ^[1-3]
French (1 ^{er} et 2 ^{ème} degree de la Langue Française)	3	3	3 ^[1-3]
<i>German</i> ^[1-3]	-	-	-
Spanish	3	2	2 ^[1-3]
Portuguese	1	1	1
Latin	-	1	-

Code

- 1 Limited conversation, reading of newspapers, routine correspondence
- 2 Engage freely in discussions read and write more difficult material
- 3 Speak, read, and write nearly as in mother tongue

Publications

50 publications, in Agents Actions, Akt. Rheumatologie, Brit. J. Dermatol., Cancer res., Eur. J. Biochem., FEBS, J. Chromatography, Lancet, PLoS NTD, Toxicol. Appl. Pharmacol., BMC, Am J Trop Med Hyg.
Holder of national and European patents, in the field of analytical biochemistry diagnostics drugs medical devices.

Publications relevant to the topic:

1. Hinz J., Hautzinger H., Stahl KW.: "Rationale for and results from a randomised, double-blind trial of tetrachlorodecaoxygen anion complex in wound healing" Lancet, 1(8485):825-8, 1986 Apr 12
2. KW Stahl in DNDi Report Paris 2006 <http://www.kinetoplastids.com/content/6/1/3>
3. KW Stahl, IG Sakhayee: „Lupoid cutaneous leishmaniasis in Afghanistan treated with 0.045% DAC N-055“ BMC Proceedings 2011, 5(Suppl 6): P247 <http://www.biomedcentral.com/content/pdf/1753-6561-5-s6-p247.pdf>
4. KW Stahl, H Darmangar: "0.045% DAC N-055 a choice for poor Afghan surgical patients?" BMC Proceedings 2011, 5(Suppl 6): P246 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239673/>
5. Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, Amin FM2, Bogdan C, and Stahl KW: „ Rapid Healing of Cutaneous Leishmaniasis by High-Frequency Electrocauterization and Hydrogel Wound Care with or without DAC N-055: A Randomized Controlled Phase IIa Trial in Kabul“ PLoS NTD 2014 in press
6. Stahl HC, Ahmadi F, Schleicher U, Sauerborn R, Bermejo JL, Amirih ML, Sakhayee I, Bogdan C, Stahl KW: "A randomized phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electrocauterization versus intralesional antimony in Afghanistan" BMC Infect Dis. 2014 Nov 25;14:619. doi: 10.1186/s12879-014-0619-8
7. Molkara S, Poursoltani E, Stahl KW, Maleki M, Khamesipour A, Bogdan C; Salehi M, Mashayekhi-Goyonlo V, "Salvage therapy with *Sodium chlorosum* (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: Results from a compassionate use study with 0.09 % *Sodium chlorosum* in amphiphilic basic cream". BMC Infectious Diseases (in press) INFD-D-18-02298R5
8. Debus D, Genç S, Kurz P, Holzer M, Bauer K, Heimke-Brinck R, Baier M, Sebald H, Debus A, Bogdan C, Stahl KW. Case Report: Local Treatment of a Leishmania tropica Infection in a Syrian Child with a Novel Filmogenic Preparation of Pharmaceutical Sodium Chlorite (LeiProtect®). Am J Trop Med Hyg. 2022 Jan 10;106(3):857-860. doi: 10.4269/ajtmh.21-0962. PMID: 35008061; PMCID: PMC8922486.